NCT01002924 - Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 11, 2013

Study Completion Date

December 11, 2013

Conditions

Solid Tumors

Interventions

DRUG

EC145

EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.

Trial Locations (1)

20817

Center for Blood and Cancer Disorders, Bethesda